<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131342" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Substance Use Disorder (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jahan</surname>
            <given-names>Azmi R.</given-names>
          </name>
          <aff>UMKC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burgess</surname>
            <given-names>Doug M.</given-names>
          </name>
          <aff>University of Missouri Kansas City</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Azmi Jahan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Doug Burgess declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131342.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Substance use disorders&#x000a0;involve&#x000a0;excessive use of&#x000a0;nicotine, alcohol,&#x000a0;and&#x000a0;other illicit&#x000a0;substances that leads to social, academic, and occupational impairment. The&#x000a0;most common&#x000a0;illicit substances&#x000a0;seen&#x000a0;include&#x000a0;cannabis, sedatives, hypnotics, anxiolytics, inhalants, opioids, hallucinogens, and stimulants. The specific factors of substance use disorder consist of abuse, intoxication,&#x000a0;and physical/psychological dependence.&#x000a0;</p>
        <p>Different&#x000a0;substances&#x000a0;can be&#x000a0;classified based&#x000a0;on their effects&#x000a0;on&#x000a0;the central nervous system.&#x000a0;These effects vary&#x000a0;depending&#x000a0;on the substance and can produce everything from increased&#x000a0;energy and euphoria to profound&#x000a0;sedation. In general, while the&#x000a0;effects vary significantly, the&#x000a0;initial&#x000a0;stages&#x000a0;of substance use disorders are characterized by&#x000a0;positive&#x000a0;reinforcement, where individuals experience&#x000a0;a sense of well-being or euphoria&#x000a0;with use.&#x000a0;As physiological and psychological dependence progresses,&#x000a0;an individual experiences negative reinforcement where substances primarily relieve dysphoria and unpleasant withdrawal symptoms.</p>
      </sec>
      <sec id="article-131342.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The cause of substance use&#x000a0;disorders&#x000a0;is multifactorial&#x000a0;and&#x000a0;includes psychological, biological, socio-cultural, and environmental&#x000a0;factors.&#x000a0;Co-morbid&#x000a0;psychiatric disorders&#x000a0;have been associated with an increased&#x000a0;risk&#x000a0;of illicit substance&#x000a0;use.&#x000a0;For example, those with attention deficit hyperactivity disorder (ADHD) and bipolar affective disorders&#x000a0;have&#x000a0;an increased risk of developing a substance use disorder in adulthood&#x000a0;compared to the general population.&#x000a0;&#x000a0;</p>
        <p>Environmental and genetic factors also play a strong role in substance use disorder.&#x000a0;An&#x000a0;individual's genetic&#x000a0;make-up for&#x000a0;stress-response&#x000a0;predisposes&#x000a0;the&#x000a0;risk of dependence on substances. Individual variations in genetics&#x000a0;have been&#x000a0;demonstrated&#x000a0;to influence stress response and predispose some individuals to develop a substance use disorder.<xref ref-type="bibr" rid="article-131342.r1">[1]</xref>&#x000a0;</p>
        <p>The Adverse Childhood Experience Study (ACES)&#x000a0;demonstrated&#x000a0;that exposure to a range of traumatic events during childhood&#x000a0;is associated with an increased risk of substance use later in life. This risk association was&#x000a0;demonstrated&#x000a0;to follow a dose-response-like pattern where increased trauma exposure was directly correlated with increased risk of developing a substance use disorder.</p>
      </sec>
      <sec id="article-131342.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The cause of substance use is multifactorial. It includes psychological, biological, socio-cultural, and environmental factors. Some mental health disorders predispose individuals to abuse illicit substances; for example, those with ADHD have a high chance of abusing illicit substances in their&#x000a0;adulthood.<xref ref-type="bibr" rid="article-131342.r1">[1]</xref></p>
        <p>Cannabis is the most common abused drug in the United States.<xref ref-type="bibr" rid="article-131342.r2">[2]</xref></p>
        <p>The Services Administration for Mental Health and Substance Abuse (SAHMSA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute of Drug Abuse (NIDA)&#x000a0;have&#x000a0;accumulated&#x000a0;data on&#x000a0;substance use and its consequences over the years. Studies show individuals who abuse one substance are more like to abuse other substances as well. In 2012, studies showed that the lifetime prevalence of alcohol use disorder was 8%, and illicit substance use was 2-3%.<xref ref-type="bibr" rid="article-131342.r3">[3]</xref></p>
        <p>A cross-sectional study was conducted&#x000a0;in the US&#x000a0;with 36,309 adults,&#x000a0;and&#x000a0;the&#x000a0;data was obtained from April 2012 to June 2013.&#x000a0;The study showed a 12-month prevalence of substance use disorder was 3.9% and lifetime substance use disorder was 9.9%.&#x000a0;Substance use disorder was more prominent among&#x000a0;certain population groups. They were&#x000a0;men, Caucasian,&#x000a0;Native Americans, young single or previously married adults, lower educated individuals, lower-income individuals, and those&#x000a0;residing&#x000a0;on the Western side of the country. There was a significant association&#x000a0;with individuals with disabilities,&#x000a0;with a&#x000a0;12-month&#x000a0;prevalence&#x000a0;of 13.5% and a lifetime prevalence of 24.6%.<xref ref-type="bibr" rid="article-131342.r4">[4]</xref></p>
      </sec>
      <sec id="article-131342.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Substance use disorders&#x000a0;involve&#x000a0;both psychological&#x000a0;and physical dependence on the substance(s) of use.&#x000a0;Severe dependence&#x000a0;is characterized by an&#x000a0;inability to&#x000a0;regulate use. Substance use disorders&#x000a0;and addiction&#x000a0;stem in part from&#x000a0;adaptive&#x000a0;changes in the brain as it&#x000a0;seeks&#x000a0;to regain&#x000a0;homeostasis.<xref ref-type="bibr" rid="article-131342.r5">[5]</xref>&#x000a0;Chronic and/or prolonged stress plays a strong role in developing drug-seeking behavior; it alters the corticotropin-releasing factor and hypothalamic-pituitary-adrenal axis (CRF/HPA)". In animal model studies, it demonstrated CRF circuitry could increase "dopamine activity in the mesolimbic reward circuit."<xref ref-type="bibr" rid="article-131342.r6">[6]</xref>&#x000a0;</p>
        <p>Stimulants,&#x000a0;specifically&#x000a0;cocaine and amphetamines,&#x000a0;exert their effect&#x000a0;by&#x000a0;preventing the recycling of&#x000a0;dopamine,&#x000a0;norepinephrine,&#x000a0;and serotonin.&#x000a0;&#x000a0;This results in&#x000a0;increased&#x000a0;concentrations&#x000a0;of&#x000a0;these&#x000a0;neurotransmitters within the synaptic&#x000a0;cleft. The&#x000a0;influx of these neurotransmitters gives the user a euphoric effect.<xref ref-type="bibr" rid="article-131342.r7">[7]</xref></p>
        <p>Worldwide and in the United States, tobacco use disorder is the most prevalent addiction.&#x000a0;&#x000a0;Most commonly,&#x000a0;nicotine&#x000a0;is&#x000a0;absorbed through the&#x000a0;lungs&#x000a0;when individuals burn and inhale tobacco products.&#x000a0;It is&#x000a0;absorbed&#x000a0;through&#x000a0;the pulmonary circulation,&#x000a0;crosses the blood-brain barrier in less than 10 seconds,&#x000a0;and attaches to the nicotinic cholinergic receptors&#x000a0;in the central nervous system&#x000a0;(CNS).&#x000a0;The metabolite of nicotine is&#x000a0;cotinine, which can be detected as a urinary marker of the substance.<xref ref-type="bibr" rid="article-131342.r8">[8]</xref>&#x000a0;Nicotine influx in&#x000a0;the CNS&#x000a0;leads&#x000a0;to neurotransmitters' release, especially&#x000a0;dopamine,&#x000a0;which&#x000a0;stimulates the brain&#x02019;s reward&#x000a0;area.&#x000a0;Chronic nicotine use&#x000a0;results in&#x000a0;tolerance,&#x000a0;when&#x000a0;excessive stimulation of&#x000a0;nicotine acetylcholine&#x000a0;receptors results&#x000a0;in&#x000a0;desensitization of the&#x000a0;receptors; these&#x000a0;neuroadaptations&#x000a0;produce&#x000a0;a state where the brain&#x000a0;requires&#x000a0;nicotine&#x000a0;to function in homeostasis.&#x000a0;This is referred to as physiological dependence.<xref ref-type="bibr" rid="article-131342.r9">[9]</xref>&#x000a0;CYP2D6 metabolizes nicotine. Therefore, it can alter the metabolism of other medications, such as antipsychotics.&#x000a0;&#x000a0;</p>
        <p>Alcohol&#x000a0;produces euphoric&#x000a0;effects&#x000a0;through the&#x000a0;dopamine neurons&#x000a0;of&#x000a0;the mesolimbic system. Alcohol&#x000a0;inhibits&#x000a0;NMDA receptors&#x000a0;and results in the&#x000a0;upregulation of&#x000a0;GABA receptors.&#x000a0;Chronic&#x000a0;consumption&#x000a0;of alcohol&#x000a0;leads&#x000a0;to&#x000a0;GABA receptor desensitization&#x000a0;and tolerance,&#x000a0;potentiating the loss of drinking control.<xref ref-type="bibr" rid="article-131342.r10">[10]</xref>&#x000a0;Alcohol is mostly absorbed in the digestive tract's mucosal lining, specifically at the proximal small intestine, where B vitamins are absorbed. Individuals who&#x000a0;drink excessively&#x000a0;may&#x000a0;have a deficiency of B vitamins.<xref ref-type="bibr" rid="article-131342.r11">[11]</xref>&#x000a0;Vitamin B1 (Thiamine) and vitamin B9 (Folic Acid) are the two most common B-vitamins&#x000a0;deficiencies. Deficiency&#x000a0;of thiamine&#x000a0;can&#x000a0;lead to neurological&#x000a0;findings such&#x000a0;as hyporeflexia&#x000a0;and&#x000a0;sensory and motor deficiency. More profound deficiencies over time can&#x000a0;lead to Wernicke's Encephalopathy and Korsakoff syndrome&#x000a0;<xref ref-type="bibr" rid="article-131342.r12">[12]</xref>. Chronic alcohol consumption can also&#x000a0;result in&#x000a0;Vitamin B9 (Folic acid) deficiency; after 8-16 weeks&#x000a0;of deficient stores of folic acid in the body,&#x000a0;individuals&#x000a0;may develop&#x000a0;"glossitis, angular stomatitis, and oral ulcers," along with "depression, irritability, insomnia, cognitive decline, fatigue, and psychosis."<xref ref-type="bibr" rid="article-131342.r13">[13]</xref></p>
        <p>Opioids&#x000a0;include&#x000a0;codeine,&#x000a0;heroin,&#x000a0;hydrocodone,&#x000a0;hydromorphone,&#x000a0;methadone,&#x000a0;meperidine,&#x000a0;morphine,&#x000a0;and&#x000a0;oxycodone.&#x000a0;Opioids&#x000a0;bind&#x000a0;to delta, kappa, and mu receptors, which&#x000a0;provide&#x000a0;analgesia for severe pain and produce euphoria feelings. Higher doses carry a risk of respiratory suppression and death.&#x000a0;Individuals with chronic exposure to opioids can experience&#x000a0;profound&#x000a0;withdrawal symptoms if opioid use is stopped abruptly. The withdrawal symptoms&#x000a0;include&#x000a0;but&#x000a0;are&#x000a0;not limited&#x000a0;to diarrhea, excess sweating, excess lacrimation, nausea, vomiting,&#x000a0;and&#x000a0;insomnia.<xref ref-type="bibr" rid="article-131342.r14">[14]</xref></p>
        <p>Sedative, Hypnotic, Anxiolytics&#x000a0;are&#x000a0;a&#x000a0;class of medications that can cause CNS depression, and if taken inappropriately, the effects can be fatal. They include&#x000a0;benzodiazepines:&#x000a0;alprazolam, clonazepam,&#x000a0;lorazepam, diazepam,&#x000a0;chlordiazepoxide; Barbiturates:&#x000a0;&#x000a0;phenobarbital, pentobarbital,&#x000a0;butabarbital; it also includes other sedative medications.&#x000a0;Other&#x000a0;classes of drugs&#x000a0;have&#x000a0;properties&#x000a0;that&#x000a0;share a similar mechanism&#x000a0;of action&#x000a0;with benzodiazepine and barbiturates.&#x000a0;These agents&#x000a0;mediate gamma-aminobutyric&#x000a0;acid (GABA) effects, producing inhibitory effects within&#x000a0;the central nervous system.&#x000a0;Alcohol can be classified in this group, but alcohol is more commonly used&#x000a0;and&#x000a0;is not utilized therapeutically, so&#x000a0;healthcare experts have classified it&#x000a0;separately.<xref ref-type="bibr" rid="article-131342.r15">[15]</xref>&#x000a0;The euphoric and sedative effects of these agents&#x000a0;precipitate&#x000a0;and perpetuate&#x000a0;a cycle of&#x000a0;overuse&#x000a0;and&#x000a0;dependence.&#x000a0;</p>
        <p>Regarding&#x000a0;cannabis, it&#x000a0;contains&#x000a0;multiple types of&#x000a0;terpenophenolic&#x000a0;compounds,&#x000a0;called&#x000a0;cannabinoids,&#x000a0;that cross the blood-brain barrier;&#x000a0;the most studied cannabinoids&#x000a0;are&#x000a0;cannabidiol&#x000a0;(CBD) and&#x000a0;tetrahydrocannabinol (THC).&#x000a0;Cannabinoids act on the cannabinoid receptors, which&#x000a0;are located in&#x000a0;the central and peripheral nervous system.&#x000a0;CBD and THC both come from the hemp plant, also known as marijuana; legal rules and regulations differentiate the definitions.&#x000a0;There are many types of hemp plants&#x000a0;that produce&#x000a0;various&#x000a0;percentages of THC and CBD.&#x000a0;Hemp has less than or equal to 0.3% of THC&#x000a0;by dry weight,&#x000a0;while marijuana&#x000a0;has more than 0.3 % of THC&#x000a0;by dry weight.&#x000a0;CBD is a&#x000a0;non-psychotropic cannabinoid&#x000a0;that does not exert euphoric properties&#x000a0;like&#x000a0;THC.<xref ref-type="bibr" rid="article-131342.r16">[16]</xref>&#x000a0;THC, the psychoactive cannabinoid,&#x000a0;exerts its effects in the brain&#x02019;s reward center in increasing dopamine levels in the prefrontal cortex,&#x000a0;providing&#x000a0;the euphoric effect.<xref ref-type="bibr" rid="article-131342.r2">[2]</xref>&#x000a0;THC activates the CB1 and CB2 receptors&#x000a0;of the endocannabinoid system, which gives&#x000a0;its&#x000a0;psychoactive properties&#x000a0;and&#x000a0;regulating eating, learning, memory, growth, development, and anxiety.<xref ref-type="bibr" rid="article-131342.r17">[17]</xref>&#x000a0;CBD&#x000a0;does not activate CB1 or CB2 receptors,&#x000a0;but limited studies show it has neuroprotective and anti-inflammatory effects.<xref ref-type="bibr" rid="article-131342.r18">[18]</xref></p>
        <p>There&#x000a0;are&#x000a0;various hallucinogens; the most common one&#x000a0;presented in the hospitals is phencyclidine or&#x000a0;phenylcyclohexyl&#x000a0;piperidine (PCP), or also known by its street name "angel&#x000a0;dust,"&#x000a0;is not only a hallucinogen but also acts as a stimulant.&#x000a0;Its mechanism of action is characterized by NMDA receptor antagonism impairing the feeling of pain and other various neurological functions and psychosis. It can also&#x000a0;facilitate&#x000a0;the increase of dopamine and norepinephrine&#x000a0;and&#x000a0;provide&#x000a0;a sympathomimetic effect.<xref ref-type="bibr" rid="article-131342.r19">[19]</xref>&#x000a0;Another common hallucinogen is&#x000a0;Lysergic acid diethylamide (LSD), or known by its street name as "acid"; it&#x000a0;has a mechanism of action that&#x000a0;is not fully understood,&#x000a0;but from studies so far, it&#x000a0;facilitates&#x000a0;serotonin receptors&#x000a0;5HT2A,&#x000a0;5HTAR, 5HT2C, and 5HT1A.&#x000a0;LSD exerts&#x000a0;receptor modulation leading to cognitive impairment and hallucinations.&#x000a0;Other hallucinogens include MDMA with street names of&#x000a0;&#x0201c;Molly, Ecstasy, X,&#x0201d;&#x000a0;another&#x000a0;hallucinogen is&#x000a0;Ketamine&#x000a0;with a street name of &#x0201c;K-Hole.&#x0201d;</p>
      </sec>
      <sec id="article-131342.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In addition to the physical exam,&#x000a0;assessment of substance use&#x000a0;should include a thorough history&#x000a0;that&#x000a0;screens several psychiatric&#x000a0;symptoms to diagnose and rule out disorders. The patient should be asked about any current life stressors, and the patient should be screened for&#x000a0;current&#x000a0;depression, mania, trauma,&#x000a0;anxiety,&#x000a0;and psychosis.&#x000a0;&#x000a0;</p>
        <p>Current substance use screening questions include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Which substance(s) are used?&#x000a0;</italic>Certain substances can cause more negatives effects than others, so&#x000a0;it is&#x000a0;important to determine which ones were used, which may help in the recovery process.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">When was the last time the substance was used, and how much and how often was it used?&#x000a0;</italic>The negative consequences of withdrawal symptoms may be fatal, such as from benzodiazepines or alcohol. If the provider was notified of the last use, then&#x000a0;appropriate treatment&#x000a0;can be administered on time. Also, recent substance use can influence an individual&#x02019;s behavior and cognitive processes, such as being agitated from Methamphetamine or Cocaine. This would help in the treatment process. For example, a patient may not need inpatient admission if the exhibited psychotic symptoms were substance-induced instead of a psychotic episode of Schizophrenia. The frequency of substance use helps&#x000a0;determine&#x000a0;the severity of the dependency.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Any experience of withdrawal symptoms?</italic>&#x000a0;Some substance use can lead to severe withdrawal symptoms. Alcohol and Benzodiazepine withdrawal can lead to seizures and have the potential to be fatal.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">What is the user&#x02019;s&#x000a0;</italic><italic toggle="yes">perception</italic><italic toggle="yes">&#x000a0;of using the substance(s)?&#x000a0;</italic>How an individual perceives illicit substances will vary from person to person.&#x000a0;Some individuals&#x000a0;use substances to cope with life stressors, while others&#x000a0;may use it as an alternative to medications such as&#x000a0;cannabis&#x000a0;for treating their anxiety.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Any feelings or readiness to change, such as cutting back use or quitting?</italic>&#x000a0;Does the patient have any cravings for the substance?&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Past Psychiatric History:&#x000a0;if the patient has any psychiatric history,&#x000a0;detailed&#x000a0;information&#x000a0;regarding&#x000a0;mental health&#x000a0;history&#x000a0;should be obtained.&#x000a0;When asking about&#x000a0;a period&#x000a0;in the past,&#x000a0;it is&#x000a0;easier to have the patient recall an event by age than recall the year. The questions to ask include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Have</italic><italic toggle="yes">&#x000a0;you&#x000a0;</italic><italic toggle="yes">been&#x000a0;</italic><italic toggle="yes">diagnosed with any psychiatric diagnosis in the past by a physician?</italic>&#x000a0;This question should be asked, and it should be verified if the diagnosis was made by a medical professional or if someone else told them the diagnosis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Any history of medication trials for substance use or other mental health disorder?</italic>&#x000a0;This open-ended question may not have a complete answer because the patient may have&#x000a0;difficulty&#x000a0;recalling the complicated names of medications from the past. If the patient affirms taking medications but cannot recall the name, an effective way&#x000a0;to get the information is to call the&#x000a0;pharmacy to get the list or get the medical records from their last prescriber.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Any history of self-harm or attempted suicide?</italic>&#x000a0;Perceptual disturbance during an intoxicated state may lead&#x000a0;to hallucinations, such as having bugs or snakes on their skin. The visual hallucinations may lead to self-harm&#x000a0;to&#x000a0;rid self of the hallucinations. Also, auditory hallucinations of commanding nature&#x000a0;may result in a&#x000a0;suicide&#x000a0;attempt. If past suicide attempts are&#x000a0;identified, then&#x000a0;it is&#x000a0;recommended to ask when the first attempt was, how many were&#x000a0;attempted, and what lead to the suicide attempts,&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Any history of violence towards others?&#x000a0;</italic>A study&#x000a0;regarding&#x000a0;ED visits due to Cocaine-induced chest pain found 40% of the patients were involved in violence a year after discharge from the ED.<xref ref-type="bibr" rid="article-131342.r20">[20]</xref>&#x000a0;Substance abuse can cause loss of impulse control and agitation, in which the user will have mood dysregulation leading to violent behavior. Obtaining history about the patient&#x02019;s history of violence enables the provider to assess for any future risks.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">At what age were the first and last&#x000a0;</italic><italic toggle="yes">psychiatric&#x000a0;</italic><italic toggle="yes">hospitalization</italic><italic toggle="yes">? How many hospitalizations&#x000a0;</italic><italic toggle="yes">regarding</italic><italic toggle="yes">&#x000a0;substance use or&#x000a0;</italic><italic toggle="yes">other&#x000a0;</italic><italic toggle="yes">mental health illness</italic><italic toggle="yes">&#x000a0;can you recall?</italic>&#x000a0;These questions should be asked in more detail and asked about the differences of being treated in the ED, such as for&#x000a0;psychiatric stability or due to intoxication, and if the patient was admitted to inpatient for stabilization. Those who are treated in the ED due to intoxication usually are stabilized and discharged after a day. But those admitted to the inpatient for psychiatric care are admitted for at least 5 days or so until they are&#x000a0;psychiatrically&#x000a0;stabilized.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Substance Use History Questions:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">At what age</italic><italic toggle="yes">&#x000a0;did</italic><italic toggle="yes">&#x000a0;the individual&#x000a0;</italic><italic toggle="yes">initiate use of</italic><italic toggle="yes">&#x000a0;the substance</italic><italic toggle="yes">?</italic>&#x000a0;This question is asked&#x000a0;because&#x000a0;substance use affects&#x000a0;brain development and&#x000a0;can&#x000a0;influence impulsive/risky behaviors from an early age.&#x000a0;Substance use at&#x000a0;an early age&#x000a0;can predispose&#x000a0;people to be cardiac and neurological disorders in adulthood.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">What benefit is sought out from substance use?</italic>&#x000a0;Those who use substances may not always use them for recreational use. Some may use it for self-treatment of their co-morbid psychiatric or medical illnesses&#x000a0;or dealing with stress. For example, those who&#x000a0;are diagnosed with&#x000a0;ADHD&#x000a0;may use Cocaine or Methamphetamine&#x000a0;as an aid to&#x000a0;focus.&#x000a0;Some&#x000a0;may use Cannabis to treat their anxiety, insomnia,&#x000a0;or neuropathic pain.&#x000a0;Therefore,&#x000a0;it is&#x000a0;important to be aware of what is the motivation behind substance use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Ha</italic><italic toggle="yes">s</italic><italic toggle="yes">&#x000a0;the individual ever&#x000a0;</italic><italic toggle="yes">attempted</italic><italic toggle="yes">&#x000a0;to cut back or stop&#x000a0;</italic><italic toggle="yes">using</italic>?&#x000a0;This question helps to&#x000a0;determine&#x000a0;the motivation for change.&#x000a0;&#x000a0;It should be followed up by questions assessing periods of success and potential barriers to implementing strategies to reduce or&#x000a0;eliminate&#x000a0;use.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Has the patient previously received treatment for a substance use disorder</italic><italic toggle="yes">?</italic>&#x000a0;Treatment options can include community&#x000a0;self-help&#x000a0;groups, outpatient treatment clinics, intensive outpatient programs, medical&#x000a0;detoxification,&#x000a0;or&#x000a0;residential treatment facilities (Rehab)</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Is there</italic><italic toggle="yes">&#x000a0;a family history of drug use</italic><italic toggle="yes">? If so, have there been any fatalities from substance use?</italic>&#x000a0;It is&#x000a0;important to be aware of any substance use by other family members because&#x000a0;family influences the individual&#x02019;s risk of substance use.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131342.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of the patient initially involves approaching the patient in a&#x000a0;non-judgmental&#x000a0;manner.&#x000a0;The provider's diction should concentrate on recovery and goal setting.&#x000a0;How&#x000a0;well&#x000a0;the first interview is conducted sets the tone for&#x000a0;establishing&#x000a0;a&#x000a0;good&#x000a0;rapport between the provider and patient.&#x000a0;The provider should always complete the history and physical for assessment.&#x000a0;Additionally, the healthcare provider should&#x000a0;obtain a full set of labs&#x000a0;to help the health provider&#x000a0;assess the patient&#x02019;s health.&#x000a0;The lab tests that are recommended&#x000a0;include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood Alcohol Level and Urine Drug Screen to screen for acute&#x000a0;substance use.&#x000a0;It is&#x000a0;usually done in the Emergency Room&#x000a0;if the patient&#x000a0;exhibits&#x000a0;agitation,&#x000a0;sedation,&#x000a0;or&#x000a0;cognitive&#x000a0;impairment.&#x000a0;Urine&#x000a0;pregnancy&#x000a0;tests should also be obtained when&#x000a0;appropriate.</p>
          </list-item>
          <list-item>
            <p>Complete Blood Count&#x000a0;(CBC)&#x000a0;may show anemia and infection, while&#x000a0;Basic Metabolic Panel&#x000a0;(BMP)&#x000a0;will show any abnormal electrolyte imbalance&#x000a0;regarding&#x000a0;substance use&#x000a0;and any other co-morbidity.</p>
          </list-item>
          <list-item>
            <p>Liver Function Test&#x000a0;and&#x000a0;Hepatitis Panel&#x000a0;can help show any negative effects on the liver from chronic alcohol use&#x000a0;or other substances; it can also show any hepatitis B&#x000a0;&#x00026;&#x000a0;C&#x000a0;infections&#x000a0;from IV drug use.&#x000a0;HIV antibody test should also be added to rule out any infection from IV drug use.</p>
          </list-item>
          <list-item>
            <p>Pancreatic Enzyme's serum level can show any issues with the pancreas from alcohol binge drinking&#x000a0;or heavy&#x000a0;nicotine use.</p>
          </list-item>
        </list>
        <p>For&#x000a0;establishing&#x000a0;a&#x000a0;diagnosis based on substance use, the DSM-5&#x000a0;is used.&#x000a0;Per DSM-5, the individual&#x000a0;must meet at least two criteria out of 11 criteria, over a 12-month period, to have substance use disorder&#x000a0;established&#x000a0;for that substance. Overall, the criteria are similar among the substances. PCP Use Disorder does not have a withdrawal criterion&#x000a0;established, so there are only 10 criteria for that disorder. Some stimulants, opioids, sedatives, anxiolytics, and hypnotics can be used under a physician&#x02019;s supervision, so tolerance is omitted for individuals taking them for treatment purposes. The 11 problems include:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>The substance use amount is taken more than what was intended and taken longer than what was&#x000a0;intended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>There is the intention and failed attempts to decrease&#x000a0;use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Extra time and effort are used to obtain and use the&#x000a0;substance or&#x000a0;recover after taking&#x000a0;them.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Having a strong craving for the substance.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The use of the substance leads to the individual unable to fulfill his or her responsibility.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Continued use of the substance despite having social and occupational impairment due to the substance use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Other activities are reduced or given up due to continued substance&#x000a0;use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Using the substance in a high-risk setting, such as when&#x000a0;operating&#x000a0;a motor vehicle or&#x000a0;operating&#x000a0;heavy machinery&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Continued use of the substance with the knowledge of the psychological and physical harmful effects caused by the substance.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tolerance development either from taking more amount of the substance to reach the same effect from last time or from having decreased effect from using the same amount of the substance.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Withdrawal symptoms are manifested after the substance use is&#x000a0;discontinued, and the withdrawal symptoms are relieved with the continuation of substance use.&#x000a0;</p>
          </list-item>
        </list>
        <p>The number of&#x000a0;criteria&#x000a0;the patient meets&#x000a0;determines&#x000a0;the severity level of the disorder; 2-3 sets the severity level as mild, 4-5 sets the severity level as moderate, and 6 or more sets the severity level as severe. A patient can relapse&#x000a0;after reaching&#x000a0;remission.&#x000a0;For the patient to be in&#x000a0;remission,&#x000a0;the&#x000a0;patient must meet at least 2 criteria, which are listed above,&#x000a0;over a 12-months period,&#x000a0;and be abstinent from substance use for at least 3 months.&#x000a0;The&#x000a0;period of&#x000a0;time&#x000a0;from 3-12 months where&#x000a0;symptoms are in&#x000a0;remission&#x000a0;is referred to as early&#x000a0;full&#x000a0;remission; after 12 months, the condition is classified as&#x000a0;sustained&#x000a0;remission.</p>
      </sec>
      <sec id="article-131342.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Currently, nicotine, alcohol, and opioids are the only substances&#x000a0;with FDA-approved medication treatments. Individuals with severe addiction may require&#x000a0;assistance&#x000a0;in a structured environment for the recovery process. The&#x000a0;<italic toggle="yes">American Society of Addiction Medicine</italic>&#x000a0;(ASAM)&#x000a0;provides&#x000a0;a&#x000a0;set of criteria for&#x000a0;individualized&#x000a0;treatment planning&#x000a0;and placement of individuals with addiction. The ASAM criteria involve six&#x000a0;dimensions:&#x000a0;intoxication/withdrawal potential, medical condition and history, mental health, individual's&#x000a0;willingness&#x000a0;to change, relapse/continue use potential, and recovery/living situation.<xref ref-type="bibr" rid="article-131342.r21">[21]</xref>&#x000a0;Patients who&#x000a0;require&#x000a0;further&#x000a0;assistance&#x000a0;after being discharged from&#x000a0;24-hour inpatient care or&#x000a0;do not&#x000a0;qualify for inpatient&#x000a0;care&#x000a0;may receive treatment from&#x000a0;intensive&#x000a0;outpatient programs (IOPs). IOPs&#x000a0;do not&#x000a0;require patients&#x000a0;to be admitted. Instead, the&#x000a0;patients&#x000a0;can stay in&#x000a0;their&#x000a0;homes while they are treated in an outpatient&#x000a0;clinic&#x000a0;for substance use during the day. IOPs comprise&#x000a0;psychosocial support, developing coping skills, and any other needed services individually.<xref ref-type="bibr" rid="article-131342.r22">[22]</xref></p>
        <p>To treat nicotine&#x000a0;use&#x000a0;disorder, bupropion, varenicline, and nicotine replacement therapy are available.&#x000a0;</p>
        <p>Bupropion&#x000a0;is a dual reuptake inhibitor of&#x000a0;dopamine and norepinephrine, which helps with nicotine cravings and withdrawal symptoms.<xref ref-type="bibr" rid="article-131342.r23">[23]</xref>&#x000a0;Varenicline has a strong affinity to nicotinic acetylcholine&#x000a0;receptors&#x000a0;and acts as a partial agonist, reducing withdrawal symptoms and blocking nicotine binding. It&#x000a0;provides&#x000a0;the same stimulation as&#x000a0;nicotine&#x000a0;and decreases the urge to use nicotine. Also, varenicline does not&#x000a0;interact with CYP450 enzymes, which can be&#x000a0;beneficial when treating&#x000a0;patients with other medications metabolized through the CYP450 pathway.<xref ref-type="bibr" rid="article-131342.r24">[24]</xref>&#x000a0;Nicotine&#x000a0;replacement therapy (NRT) with&#x000a0;patches and nicotine gum&#x000a0;help with cravings and withdrawal symptoms. Some studies show a combination of the gum and the patch improves smoking cessation rates.<xref ref-type="bibr" rid="article-131342.r25">[25]</xref>&#x000a0;In any&#x000a0;clinical setting,&#x000a0;healthcare providers&#x000a0;should&#x000a0;provide&#x000a0;education and resources for smoking cessation, as the health benefits of smoking cessation&#x000a0;are significant.&#x000a0;</p>
        <p>For stimulant use disorder, such as with cocaine and amphetamine drugs,&#x000a0;there are no approved pharmacological treatments.<xref ref-type="bibr" rid="article-131342.r26">[26]</xref>&#x000a0;However,&#x000a0;non-pharmacological therapy, such as&#x000a0;contingency management, is available;&#x000a0;it&#x000a0;involves operant conditioning&#x000a0;reinforcement. The goal of the treatment is to influence a certain type of behavior via behavioral rewards. In substance use, behavior is&#x000a0;modified&#x000a0;by&#x000a0;providing&#x000a0;a&#x000a0;reward&#x000a0;in exchange for the desired behavior, such as&#x000a0;decrease substance use or abstinence.<xref ref-type="bibr" rid="article-131342.r27">[27]</xref></p>
        <p>The FDA approves acamprosate, naltrexone, and disulfiram to treat alcohol use disorder.<xref ref-type="bibr" rid="article-131342.r28">[28]</xref>&#x000a0;Disulfiram, an aldehyde dehydrogenase inhibitor, produces an unpleasant set of symptoms such as headache, nausea, vomiting, flushing, dizziness, and weakness when alcohol is consumed to&#x000a0;prevent further alcohol consumption.<xref ref-type="bibr" rid="article-131342.r29">[29]</xref>&#x000a0;Naltrexone blocks the central mu-receptor, reducing cravings, and aids in preventing relapse to alcohol use.<xref ref-type="bibr" rid="article-131342.r30">[30]</xref>&#x000a0;Acamprosate aids in reducing withdrawal symptoms by countering excessive NMDA receptor activation from alcohol withdrawal. In the clinical setting,&#x000a0;it is&#x000a0;important to&#x000a0;include&#x000a0;vitamin B1 and vitamin B9, along with multivitamins&#x000a0;supplements, to address&#x000a0;any nutritional&#x000a0;deficiencies.&#x000a0;&#x000a0;</p>
        <p>For&#x000a0;opioid&#x000a0;use&#x000a0;disorder,&#x000a0;several treatment options are available. They&#x000a0;include&#x000a0;methadone, naltrexone, and buprenorphine, which are&#x000a0;frequently&#x000a0;combined with naloxone to reduce the risk of&#x000a0;misuse. Methadone (full&#x000a0;mu&#x000a0;agonist)&#x000a0;can only be&#x000a0;used to treat opioid use disorder by specific treatment facilities&#x000a0;designated&#x000a0;as Opioid Treatment Programs (OTPs). Methadone has decades of research&#x000a0;demonstrated&#x000a0;reduced&#x000a0;illegal drug use, criminal activity,&#x000a0;mortality, and morbidity, buprenorphine-naloxone (partial agonist at the mu-opioid receptor). As a partial agonist,&#x000a0;this&#x000a0;agent&#x000a0;has&#x000a0;less potential for&#x000a0;overdose.<xref ref-type="bibr" rid="article-131342.r14">[14]</xref>&#x000a0;During opioid withdrawal, the patient&#x000a0;can experience dysregulated mood, dyssomnia, pupillary&#x000a0;dilation, muscle pain, nausea, vomiting, excessive lacrimation, and other symptoms. The (Clinical Opiate Withdrawal Scale) COWS scale is an 11-item rating system used to measure the severity of opioid withdrawal; a score of 5 or above&#x000a0;indicates active&#x000a0;withdrawal. Clonidine, an alpha-2 receptor agonist, may help reduce the severity of withdrawal symptoms and stabilize blood pressure. Loperamide may also be needed to aid the patient's GI effect in the setting of repeated diarrhea during withdrawal.<xref ref-type="bibr" rid="article-131342.r31">[31]</xref></p>
        <p>
<bold>Mainstreaming Addiction Treatment (MAT) Act</bold>
</p>
        <p>The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to p escribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and will integrate substance use disorder treatment across healthcare settings.&#x000a0;</p>
        <p>As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law, and SAMHSA encourages them to do so. Prescribers who were registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed on the part of registrants.</p>
        <p>There are no longer any limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required.&#x000a0;</p>
        <p>Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and does not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information in order to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with OUD. Contact information for State Opioid Treatment Authorities can be found here:&#x000a0;https://www.samhsa.gov/medicationassisted-treatment/sota.</p>
      </sec>
      <sec id="article-131342.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Depression can be&#x000a0;exhibited&#x000a0;from opioids, alcohol, sedative, anxiolytic, hypnotic, and cannabis&#x000a0;use.&#x000a0;It is also associated with withdrawal from&#x000a0;stimulants.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mania&#x000a0;and anxiety can be&#x000a0;exhibited&#x000a0;from stimulants&#x000a0;(cocaine and amphetamine).&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Psychosis can be&#x000a0;associated with substances but varies from individual to individual and with time.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131342.s9" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Patients who are&#x000a0;physically dependent on sedative effects often require medication during the&#x000a0;detoxification&#x000a0;process to minimize the risks associated with complicated withdrawal. Acute intoxication can present with&#x000a0;slurred speech, cognitive impairment, poor coordination, and unsteady&#x000a0;gait.&#x000a0;For&#x000a0;alcohol&#x000a0;and benzodiazepine&#x000a0;withdrawal,&#x000a0;the&#x000a0;Clinical Institute Withdrawal Assessment (CIWA)&#x000a0;scale&#x000a0;helps&#x000a0;determine the frequency of medication dosing to prevent withdrawal complications.&#x000a0;In an emergency setting, treatment for alcohol&#x000a0;and benzodiazepine&#x000a0;intoxication is primarily supportive, with close monitoring of&#x000a0;vitals.&#x000a0;Benzodiazepines are considered a first-line treatment to prevent worsening withdrawal symptoms.<xref ref-type="bibr" rid="article-131342.r32">[32]</xref>&#x000a0;In cases of severe benzodiazepine intoxication, particularly if the patient is becoming hypoxic, flumazenil&#x000a0;may be indicated.&#x000a0;Flumazenil reduces the&#x000a0;expression of GABA&#x000a0;subunit&#x000a0;receptors,&#x000a0;reversing&#x000a0;the effect of benzodiazepines.<xref ref-type="bibr" rid="article-131342.r33">[33]</xref></p>
        <p>For opioid intoxication,&#x000a0;naloxone is used&#x000a0;to reverse respiratory depression&#x000a0;caused by opioid overdose.&#x000a0;Naloxone is a competitive mu-opioid receptor antagonist, which reverses the effects of opioids.&#x000a0;It can be administered intramuscularly, intravenously, or&#x000a0;nasally; the fastest route of administration is intravenous.<xref ref-type="bibr" rid="article-131342.r34">[34]</xref></p>
        <p>For PCP intoxication, the&#x000a0;focus&#x000a0;is stabilizing the patient with supportive care.&#x000a0;The patient&#x000a0;may exhibit&#x000a0;ataxia, nystagmus, increase cardiac workload, muscle&#x000a0;rigidity,&#x000a0;and seizures.&#x000a0;Hyperacusis is another side-effect of PCP use, which is why it may be necessary to place the patient in a low stimulus environment. A high stimulus&#x000a0;environment may trigger&#x000a0;agitation&#x000a0;and increase the likelihood that&#x000a0;restraints are required. In some cases, gastric&#x000a0;suction&#x000a0;or the use of activated charcoal may be indicated. Benzodiazepines&#x000a0;may&#x000a0;help to control agitation and reduce the risk of seizures.<xref ref-type="bibr" rid="article-131342.r19">[19]</xref></p>
      </sec>
      <sec id="article-131342.s10" sec-type="Staging">
        <title>Staging</title>
        <p>During the&#x000a0;recovery process&#x000a0;of substance use, the individual transitions through&#x000a0;various stages&#x000a0;of change, demonstrated&#x000a0;as the stages of change model.&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Precontemplation,&#x000a0;when the individual does not recognize the negative effects of substance use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Contemplation,&#x000a0;when the issues of substance use are recognized, yet&#x000a0;no action is taken.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Preparation, when the individual has considered making a change&#x000a0;regarding&#x000a0;substance&#x000a0;use and&#x000a0;begins to make minor changes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Action&#x000a0;is the&#x000a0;stage when the individual makes significant changes to prevent substance use, such as avoiding triggers or reaching out for help.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Maintenance, the stage when the action stage is&#x000a0;maintained&#x000a0;to&#x000a0;prevent substance use.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Relapse, the stage when the substance use is&#x000a0;restarted.<xref ref-type="bibr" rid="article-131342.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131342.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Individuals who abuse&#x000a0;substances&#x000a0;for&#x000a0;a chronic period&#x000a0;develop extreme dependence&#x000a0;on them. If the&#x000a0;individual&#x000a0;attempts to stop using&#x000a0;it, their withdrawal symptoms&#x000a0;become&#x000a0;severe enough for the individual to&#x000a0;restart the abuse cycle.&#x000a0;There are predicting factors that influence the outcome for the individual; the degree of relationship between the predictor factor and the outcome varies&#x000a0;from&#x000a0;person to person.&#x000a0;Some of the predicting&#x000a0;factors include but not limited to are the degree of dependence and withdrawal, the motivation to be committed to abstinence, treatment timeframe, genetics, the severity of cravings, and how the individual copes during stressful situations.<xref ref-type="bibr" rid="article-131342.r36">[36]</xref></p>
      </sec>
      <sec id="article-131342.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of substance use&#x000a0;are&#x000a0;broad.&#x000a0;</p>
        <p>Substance use will impact&#x000a0;multiple systems of the body, including but not limited to neurologic,&#x000a0;endocrine,&#x000a0;psychiatric,&#x000a0;cardiopulmonary, hepatic,&#x000a0;hematologic, and&#x000a0;immunologic.&#x000a0;These problems include&#x000a0;but not limited to are:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Stroke&#x000a0;and seizures&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Loss of nerve functions leading to muscle weakness and loss of&#x000a0;sensation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Memory&#x000a0;loss and overall&#x000a0;cognitive deficits.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Various forms of psychosis,&#x000a0;loss of impulse control,&#x000a0;personality change,&#x000a0;and&#x000a0;mood dysregulation.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coma and death&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased cardiac workload and with chronic use cardiac&#x000a0;failure.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nasal Septal Perforation&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Respiratory depression&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Muscle breakdown from overuse, leading to&#x000a0;rhabdomyolysis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Liver failure and hepatocellular carcinoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatitis B &#x00026; C infections, HIV, sepsis, and gangrene</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-131342.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Substance use frequently starts at&#x000a0;an early age, so education of the general population starting in school can reduce the prevalence of substance&#x000a0;use disorders.&#x000a0; Identifying high-risk patient populations and reducing care barriers can help limit the negative impact of substance use disorders.</p>
      </sec>
      <sec id="article-131342.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective&#x000a0;education&#x000a0;on the treatment of substance use disorders among&#x000a0;healthcare providers&#x000a0;can help&#x000a0;to improve outcomes.&#x000a0;Unfortunately,&#x000a0;training in substance-related/addictive disorders is frequently limited, leaving providers ill-equipped to meet the demand after training. Additionally, a&#x000a0;lack of adequate curriculum&#x000a0;for healthcare provider training&#x000a0;and a negative view of patients with substance use disorders plays a role&#x000a0;in poor&#x000a0;healthcare&#x000a0;outcomes.<xref ref-type="bibr" rid="article-131342.r37">[37]</xref></p>
        <p>Unless&#x000a0;emergency&#x000a0;treatment&#x000a0;requires it, prescribing potentially addictive&#x000a0;medications should&#x000a0;be&#x000a0;limited&#x000a0;to&#x000a0;healthcare&#x000a0;providers specifically&#x000a0;trained in substance-related/addictive disorders. When utilizing medications in the treatment of substance use disorders, healthcare providers should not place arbitrary limits on treatment duration. All treatment decisions should be patient-centered and based on the&#x000a0;unique risk/benefit analysis.&#x000a0; The&#x000a0;<italic toggle="yes">American Academy of Addiction Psychiatry</italic><italic toggle="yes">&#x000a0;(AAAP),</italic>&#x000a0;along with the Substance Abuse and Mental Health Services Administration (SAMHSA), sponsors&#x000a0;Providers Clinical Support System&#x000a0;(PCSS), a&#x000a0;training&#x000a0;program&#x000a0;for physicians and other healthcare providers. This program offers training, mentorship, and other support for individuals interested in preventing, identifying, and treating opioid use disorders.&#x000a0;</p>
        <p>Dealing with substance use disorder requires the efforts of all members of the interprofessional healthcare team, including clinicians, mid-level practitioners, nursing staff, and pharmacists, who can coordinate their activities and engage in open communication to help identify substance use disorder, streamline treatment, and watch for signs of relapse once therapy has been initiated. This interprofessional approach stands the best chance of patient success in recovering from substance use disorder. [Level 5]</p>
      </sec>
      <sec id="article-131342.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131342&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131342">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131342/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131342">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131342.s16">
        <title>References</title>
        <ref id="article-131342.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranzler</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>What is addiction?</article-title>
            <source>Alcohol Res Health</source>
            <year>2008</year>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-5</page-range>
            <pub-id pub-id-type="pmid">23584810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostwick</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Blurred boundaries: the therapeutics and politics of medical marijuana.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-86</page-range>
            <pub-id pub-id-type="pmid">22305029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merikangas</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>McClair</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of substance use disorders.</article-title>
            <source>Hum Genet</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>779</fpage>
            <page-range>779-89</page-range>
            <pub-id pub-id-type="pmid">22543841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hasin</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">26580136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Chronic stress, drug use, and vulnerability to addiction.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>1141</volume>
            <fpage>105</fpage>
            <page-range>105-30</page-range>
            <pub-id pub-id-type="pmid">18991954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartwell</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tolliver</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Biologic Commonalities between Mental Illness and Addiction.</article-title>
            <source>Prim psychiatry</source>
            <year>2009</year>
            <month>Aug</month>
            <day>01</day>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>33</fpage>
            <page-range>33-39</page-range>
            <pub-id pub-id-type="pmid">26030747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Richards</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <chapter-title>Methamphetamine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28613645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Widysanto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Combest</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Dhakal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Nicotine Addiction</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29763090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benowitz</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.</article-title>
            <source>Annu Rev Pharmacol Toxicol</source>
            <year>2009</year>
            <volume>49</volume>
            <fpage>57</fpage>
            <page-range>57-71</page-range>
            <pub-id pub-id-type="pmid">18834313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Alcohol Addiction, Gut Microbiota, and Alcoholism Treatment: A Review.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Sep</month>
            <day>03</day>
            <volume>21</volume>
            <issue>17</issue>
            <pub-id pub-id-type="pmid">32899236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cylwik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chrostek</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Disturbances of folic acid and homocysteine metabolism in alcohol abuse].</article-title>
            <source>Pol Merkur Lekarski</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>178</issue>
            <fpage>295</fpage>
            <page-range>295-9</page-range>
            <pub-id pub-id-type="pmid">21595178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Wiley</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Vitamin B1 (Thiamine) Deficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30725889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Folic Acid Deficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30570998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Azadfard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huecker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Leaming</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Addiction</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">28846246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simone</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bobrin</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <chapter-title>Anxiolytics and Sedative-Hypnotics Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">32965980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lachenmeier</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Habel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herbi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zerbe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rajcic de Rezende</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Walch</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Sproll</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?</article-title>
            <source>F1000Res</source>
            <year>2019</year>
            <volume>8</volume>
            <fpage>1394</fpage>
            <pub-id pub-id-type="pmid">32117565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alger</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Supply and demand for endocannabinoids.</article-title>
            <source>Trends Neurosci</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>304</fpage>
            <page-range>304-15</page-range>
            <pub-id pub-id-type="pmid">21507493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devinsky</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cilio</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fernandez-Ruiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Marzo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jutras-Aswad</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Notcutt</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Martinez-Orgado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rohrback</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Whalley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.</article-title>
            <source>Epilepsia</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>791</fpage>
            <page-range>791-802</page-range>
            <pub-id pub-id-type="pmid">24854329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Journey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <chapter-title>Phencyclidine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29939642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walton</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chermack</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Predictors of violence following Emergency Department visit for cocaine-related chest pain.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2009</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1-3</issue>
            <fpage>79</fpage>
            <page-range>79-88</page-range>
            <pub-id pub-id-type="pmid">18722724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kenefake</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>An Argument for Change in Tobacco Treatment Options Guided by the ASAM Criteria for Patient Placement.</article-title>
            <source>J Addict Med</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>291</fpage>
            <page-range>291-9</page-range>
            <pub-id pub-id-type="pmid">27466070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braude</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Dougherty</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ghose</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Delphin-Rittmon</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Substance abuse intensive outpatient programs: assessing the evidence.</article-title>
            <source>Psychiatr Serv</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>718</fpage>
            <page-range>718-26</page-range>
            <pub-id pub-id-type="pmid">24445620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Prince</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Substance Use in Pregnancy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">31194470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jordan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Xi</surname>
                <given-names>ZX</given-names>
              </name>
            </person-group>
            <article-title>Discovery and development of varenicline for smoking cessation.</article-title>
            <source>Expert Opin Drug Discov</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>671</fpage>
            <page-range>671-683</page-range>
            <pub-id pub-id-type="pmid">29587555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sealock</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Smoking Cessation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">29494049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sofuoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sewell</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Norepinephrine and stimulant addiction.</article-title>
            <source>Addict Biol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-29</page-range>
            <pub-id pub-id-type="pmid">18811678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McPherson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Burduli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Herron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oluwoye</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hirchak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>McDonell</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Roll</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies.</article-title>
            <source>Subst Abuse Rehabil</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>43</fpage>
            <page-range>43-57</page-range>
            <pub-id pub-id-type="pmid">30147392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Egli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Noronha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Medications for alcohol use disorders: An overview.</article-title>
            <source>Pharmacol Ther</source>
            <year>2018</year>
            <month>May</month>
            <volume>185</volume>
            <fpage>64</fpage>
            <page-range>64-85</page-range>
            <pub-id pub-id-type="pmid">29191394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Stokes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdijadid</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Disulfiram</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">29083801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Theriot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sabir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azadfard</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Antagonists</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30725764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huecker</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <chapter-title>Opioid Withdrawal</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30252268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>LaHood</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <chapter-title>Ethanol Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">32491313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuver</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil decreases surface expression of &#x003b1;4&#x003b2;2&#x003b4; GABAA receptors by increasing the rate of receptor internalization.</article-title>
            <source>Brain Res Bull</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>120</volume>
            <fpage>131</fpage>
            <page-range>131-43</page-range>
            <pub-id pub-id-type="pmid">26592470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jordan</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Morrisonponce</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Naloxone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">28722939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Roberto</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The addicted brain: understanding the neurophysiological mechanisms of addictive disorders.</article-title>
            <source>Front Integr Neurosci</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">25852502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciraulo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Piechniczek-Buczek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iscan</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Outcome predictors in substance use disorders.</article-title>
            <source>Psychiatr Clin North Am</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <page-range>381-409</page-range>
            <pub-id pub-id-type="pmid">12778840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131342.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crockford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fleury</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Charney</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>el-Guebaly</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Training in Substance-Related and Addictive Disorders, Part 2: Updated Curriculum Guidelines.</article-title>
            <source>Can J Psychiatry</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">26720815</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
